Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVX-sCPD9 Intranasal Booster Vaccine in Previously Vaccinated Adults
NCT07703475Phase 1Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of RVX-sCPD9 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of abnormal clinical safety laboratory adverse events at 15 days, Occurrence of Adverse Events of Special Interest at 181 days and 6 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
RVX-sCPD9
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07703475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07703475.